LB100

SKU: orb1302850

Description

LB100

Research Area

Metabolism Research

Key Properties

• CAS Number: 1632032-53-1
• MW: 268.31
• Purity: 98.63%
• Formula: C₁₃H₂₀N₂O₄
• SMILES: C(=O)(C1[C@]2(O[C@@](C1C(O)=O)(CC2)[H])[H])N3CCN(C)CC3
• Target: Phosphatase
• Solubility: DMSO:< 1 mg/mL (insoluble or slightly soluble);H2O:67.5 mg/mL (251.57 mM);Ethanol:< 1 mg/mL (insoluble or slightly soluble)

Bioactivity

• Target IC50:
  PP2A(BxPc-3):0.85 μM|PP2A(Panc-1):3.87 μM
• In Vivo:
  Compared to the control group, LB-100 significantly increased the intracellular concentration of doxorubicin by approximately 2.5 times, enhancing the tumor cells' sensitivity to doxorubicin. Additionally, LB-100 amplified the secretion of vascular endothelial growth factor, thereby promoting angiogenesis mediated by HIF-1α-VEGF. LB-100 also demonstrated a notable inhibitory effect on the growth of BxPc-3 (IC50: 2.3 μM) and Panc-1 (IC50: 1.7 μM) cells. Following treatment with LB-100, a reduction of 30-50% in PP2A activity was observed in BxPc-3, SW1990, and Panc-1 tumor cells.
• In Vitro:
  In xenograft mouse models of pancreatic cancer, LB-100 (2 mg/kg, i.p.) enhances the therapeutic efficacy of the chemotherapy agent doxorubicin. LB-100 increases both the blood flow velocity on the tumor surface and the microvascular density of the tumor.
• Cell Research:
  Cytotoxicity is conducted by using a Cell Counting Kit-8. Cells are seeded in 96-well plates with a density of 3000 cells per well and are assessed after treatments following the CCK-8 protocol. Relative cytotoxicity is expressed as a percentage of speci c controls. (Only for Reference)

Storage & Handling

• Storage: store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

PP2A, LB 100, LB100, LB-100

Compound Identifiers

PubChem CID

45101433